Brief: Kintor Pharmaceutical Says Successful Completion Of Phase Ii Clinical Trial Of Kx-826
11/05/2023 15:20
May 11 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* SUCCESSFUL COMPLETION OF PHASE II CLINICAL TRIAL OF KX-826
FOR
TREATMENT OF AGA IN UNITED STATES
Source text for Eikon: ID:nHKSbhjcQ2
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint